| Similar Articles |
|---|
 |
Nurse Practitioner
August 2011
Davis et al. |
Supportive approaches for Alzheimer Disease Alzheimer disease accounts for almost 80% of all dementia diagnoses. Currently, more than 5 million Americans suffer from this debilitating illness, with the highest prevalence in the oldest age groups.   |
Managed Care
December 2005
David S. Geldmacher |
The Cost Benefit to Health Plans of Pharmacotherapy for Alzheimer's Disease As with other chronic diseases of aging, early diagnosis and pharmacologic therapy may reduce the costs for enrollees with Alzheimer's disease. This article reviews patient and caregiver outcomes associated with reduced health care costs and their implications for Managed Care Organizations. |
Nursing
February 2010
Daniel A. Hussar |
New Drugs 2010, PART 1 In this article, you'll learn about 16 new drugs. |
Nursing
June 2011
Daniel A. Hussar |
New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis. |
Nursing
March 2012
Daniel A. Hussar |
New Drugs 2012: part I In this article, you'll learn about 11 recently approved drugs. |
Nursing
June 2010
Daniel A. Hussar |
New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs. |
Chemistry World
October 8, 2010
Sarah Houlton |
U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness. |
Nursing
February 2009
Daniel A. Hussar |
New Drugs 09: Part 1 Learn about 10 new drugs, including nebivolol HCl, the newest beta-adrenergic blocking agent for hypertension. |
American Family Physician
June 15, 2002
Jeffrey L. Cummings |
Guidelines for Managing Alzheimer's Disease: Part II. Treatment Once the clinical diagnosis of Alzheimer's disease has been made, a treatment plan must be developed. Patient symptoms and care needs change as Alzheimer's disease progresses. |
Nurse Practitioner
February 2011
Jennifer M. Belavic |
Annual Drug Update: 2010 in Review In 2010, the FDA approved several new drugs and new indications for use in primary care. From new therapies for adults with rheumatoid arthritis to a combination drug for benign prostatic hyperplasia, NPs need to be aware of the latest medications now available. |
Chemistry World
July 3, 2014
Maria Burke |
Renewed focus on dementia checked by drug challenges The risks and barriers for companies working in dementia are huge, but so too, potentially, are the rewards, says Simon Ridley, head of research at Alzheimer's Research UK. |
The Motley Fool
May 30, 2006
Rich Duprey |
NICE Not Playing Nice With Alzheimer's The British health authority proposes limiting availability of Alzheimer's treatments because of cost. What will this mean to drug-makers and their shareholders? |
The Motley Fool
October 13, 2006
Rich Duprey |
NICE Is Just Dumb The British health agency prohibits the use of certain Alzheimer's treatments because of cost. |
Chemistry World
May 27, 2015
Phillip Broadwith |
Actavis plan to thwart generics blocked A US court has blocked Ireland-based firm Actavis's attempt to forcibly shift patients onto an extended release version of one of its drugs by withdrawing the original formulation from the market. |
Pharmaceutical Executive
November 1, 2012
Sue Barrowcliffe |
Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options. |
The Motley Fool
August 31, 2009
Brian Orelli |
Don't Let Dummy Pills Make You a Dummy Investor Instead of being scared that the sugar pill will perform better than expected, pharma investors should factor it in and require more information before investing in companies with drugs that may be affected by it.. |
Chemistry World
November 2, 2006
Michael Gross |
Alzheimer's Century Researchers worldwide are commemorating the centenary of Alois Alzheimer's first description of the dementia named after him. |
Wired
August 24, 2009
Steve Silberman |
Placebos Are Getting More Effective. Drugmakers Are Desperate to Know Why. The fact that taking a faux drug can powerfully improve some people's health -- the so-called placebo effect -- has long been considered an embarrassment to the serious practice of pharmacology. |
The Motley Fool
August 13, 2007
Rich Duprey |
U.K. High Court Forgets to Be NICE A court challenge to place limits on treatment for Alzheimer's disease is upheld. Eisai has said it will appeal the High Court's ruling. It's a bit of a high-stakes gamble. The United Kingdom accounts for just a small portion of Eisai's profits from Aricept. |
The Motley Fool
June 29, 2007
Rich Duprey |
No More Mr. NICE Guy Pharmaceuticals take British advisory agency to court to approve Alzheimer's treatment. |
